MTP-101

**MTP-101** is an investigational oral microbiome therapy based on healthy-donor fecal microbiota transplantation. Public sources show that the exact umbrella code \"MTP-101\" is used across at least two formulation-specific products: **MTP-101-C**, an encapsulated fecal microbiota product, and **MTP-101P**, a purified freeze-dried powder formulation. These products are being studied in conditions linked to gut dysbiosis and immune dysfunction, including immune-mediated colitis, immune-related dermatitis, hepatic encephalopathy, and Pitt-Hopkins syndrome with gastrointestinal symptoms. Mechanistically, MTP-101 is intended to restore a disrupted intestinal microbial community, promote donor-bacteria engraftment, suppress pathobionts, and modulate local and systemic immune signaling rather than act through a single defined molecular target. Because the query is exactly \"mtp-101\" rather than a formulation-specific code, the most accurate annotation is as a non-specific parent microbiota-transfer product family rather than one uniquely defined finished drug product.

Other names

microbiota transfer therapyMTT